-
J Hepatol: Hepatic cell NRF2 specific activation regulates the occurrence of liver fibrosis and liver cancer
Time of Update: 2021-01-29
In fatty liver mice, oxidation should surge and be strongly associated with NRF2 target gene activation in mice, microarray analysis showed that the absence of Keap1 induced NRF2 target genes to participate in glutathione metabolism and heterogeneity stress (e.g., Nqo1).
-
FDA approves Opdivo in joint Cabometyx for the treatment of advanced renal cell carcinoma
Time of Update: 2021-01-29
The U.S. Food and Drug Administration (FDA) said recently that it has approved a joint first-line treatment for patients with advanced renal cell carcinoma (RCC) using the anti-PD-1 antibody Opdivo (nivolumab) and Exelixis' tyrosine kinase inhibitor Cabozantinib.
-
J Thromb Haemost: Pulmonary embolism during autopsy for cancer patients
Time of Update: 2021-01-29
, researchers tried to estimate the proportion of cancer patients with PE at the time of the autopsy, according to a recent study published in Journal of Thrombosis and Haemostasis, an authoritative journal of thrombosis and clotting diseases.
-
Br J Cancer: Fecal Immunochemical Test (FIT): A new diagnostic option for patients with low-risk symptoms of colorectal cancer
Time of Update: 2021-01-29
, the results showed that FIT did well in classifying patients with low-risk symptoms of colorectal cancer in primary care.
-
25-year-old woman diagnosed with liver cancer! This habit is the culprit.
Time of Update: 2021-01-29
Although the symptoms of liver cancer are not obvious, but people with these characteristics should be careful to get liver cancer: 1, had hepatitis B in china, about 90% of liver cancer patients have been infected with hepatitis B virus.
-
Lancet Diabetes Endocrinol: Trends in the incidence of thyroid cancer in children/adolescents worldwide
Time of Update: 2021-01-29
Researchers screened data from the International Child Cancer Volume 3 Research Database, the World Health Organization Mortality Database and the Cancer Morbidity Database on five continents, conducted population-based studies on the incidence and mortality of thyroid cancer in children and adolescents aged 0-19 years, and analysed time-varying trends in morbidity, including absolute changes in morbidity, and the correlation between childhood and adolescent morbidity and adult morbidity.
-
JAMA Oncology: Start using aspirin at a young age and the risk of colorectal cancer is significantly reduced!
Time of Update: 2021-01-29
, however, studies have shown that regular use of aspirin reduces the incidence of colorectal cancer in middle-age people, but at the same time increases side effects such as gastrointestinal bleeding.
-
18F-FLT PET ococytosis predicts the progression of meningococ
Time of Update: 2021-01-27
Meningoma is a common primary intracranial tumor in adults, in recent years, with the popular application of imaging examination, asymptomatic meningoma detection rate is increasing, but there is no
-
Innovative treatments for stomach cancer! Redding Pharmaceuticals / FivePrime pioneered FGFR2b targeted single-anti-bemarituzumab plus chemotherapy first-line treatment with strong efficacy!
Time of Update: 2021-01-27
results showed that in newly diagnosed patients with fibroblast growth factor-positive (FGFR2b plus), non-HER2-positive, advanced gastric or gastroesophageal joint (GEJ) cancer, bemarituzumab significantly improved progression-free survival compared to placebo when combined chemotherapy was used for first-line treatment (median PF) S: 9.5 months vs 7.4 months; HR s 0.68), total lifetime (mid OS: not up to vs 12.9 months; HR s 0.58), total mitigation rate (ORR: 46.8% vs 33.3%).
-
First-line treatment for pancreatic cancer! CD73 inhibitor AB680 plus chemotherapy and anti-PD-1 therapy has strong efficacy: total remission rate of 41%, disease control rate of 85%!
Time of Update: 2021-01-27
(results detailed in: ARC-8: Phase 1/1b Study to Evaluate Safety and Tolerability of AB680 , Between and Zimberelimab (AB122) in Patients Treatment with-Naive Metastatic Pancreatic Adenocarcinoma AB68 0 (Photo source: tsbiochem.com) AB680 is an ultra-powerful, selective small molecule CD73 inhibitor designed to provide benefits different from monoclonal antibodies, such as stronger inhibition of CD73 enzyme activity (soluble and cell-binding) and deeper tumor penetration.
-
Postoperative ancillary treatment of esophageal cancer/gastroesophageal cancer! Hundreds of times the United Opdivo (Odivo) into the Eu review: significantly extend the disease-free life!
Time of Update: 2021-01-27
January 14, 2021 // -- The European Medicines Agency (EMA) has accepted Opdivo (Odivo, generic name: nivolumab, A marketing authorization application (MAA) for Navuliyu monotherapy (MAA) as an ancillary therapy for adult patients with esophageal or gastroesophageal connections (GEJ) cancers with new assisted synchritis chemotherapy (CRT) and residual pathological diseases after excision.
-
Anti-PD-1 therapy! GlaxoSmithKline's treatment of mismatch repair defects (dMMR) solid tumors is strong: total remission rate 36-43%!
Time of Update: 2021-01-27
JANUARY 16, 2021 // -- GlaxoSmithKline (GSK) recently released the latest data on the anti-PD-1 therapy dostarlimab (formerly TSR-042) GARNET Research Queue F at the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI).
the society assessed the efficacy and safety of dostarimab treatment mismatch repair defects (dMMR) non-endometrial advanced solid tumors.
-
Tumor immunotherapy upgrade! AstraZenecom's New Dosing Scheme (1500mg once every 4 weeks) has been approved in the EU!
Time of Update: 2021-01-27
January 15, 2021 // -- AstraZeneca recently announced that the European Commission (EC) has approved a new dose option for anti-PD-L1 therapy Imfinzi (Infinfan, generic name: durvalumab, dovalyu monoanti) every 4 Mondays A secondary fixed dose of 1500 mg for approved non-small cell lung cancer (NSCLC) adaptation, specifically for adult patients with local late stage or non-removable NSCNC after receiving platinum-containing chemotherapy (CRT), tumor expression PD-L1 (≥1% tumor cells).
-
Nature sub-journal paper details! CAR-T cells targeting CXCR5 are expected to treat feliestic lymphoma and chronic lymphocytic leukemia
Time of Update: 2021-01-27
In the new study, a team led by Dr. Uta Hoepken, head of the Autoimmune and Tumor Microenvironigning Laboratory at Max Delbrook Molecular Medical Center, developed a new form of therapy that allows T-cells in the lab to be sensitive to different identification characteristics--- the B-cell home protein CXCR5.
-
IDH wild 胝 surgical treatment of glioblastoma
Time of Update: 2021-01-26
the authors screened IDH wild ccGBM patients older than 18 years of age through MRI imaging, confirmed by histological pathology and molecular gene analysis, and divided into three groups: tumor full cut, sub-full cut and stereotactic biopsy.
-
CD30 CAR-T Cell Therapy! Singapore Tesha Bio-Innovative Therapy is eligible for EU Priority Drug (PRIME): Treatment of Lymphoma (cHL)!
Time of Update: 2021-01-26
recently announced that the European Medicines Agency (EMA) has granted its CD30 directed self-embedded antigen-treated antigen-treated T-cell (CD30 CAR-T) therapy priority drug qualification (PRIME) for the treatment of recurring or refractic classic Hodgkin's lymphoma (R/R cHL).
-
Immunolight Activates Cancer Therapy! FDA Grants Padeliporfin ImPACT Fast Track Qualification: Treatment of Upper Urethroid Skin Cancer (UTUC)!
Time of Update: 2021-01-26
Steba biotech focuses on the development of Padeliporfin ImPACT as an innovative oncology platform with the potential to provide surgical-like efficacy and retain organs in UTUC and other solid tumors.
-
Professor Meng Zhiqiang | IMbrave150 study OS results "re-record", "T-A" to open a new chapter in HCC treatment
Time of Update: 2021-01-26
China is a "big country of liver cancer", China's annual liver cancer cases and deaths accounted for more than half of the world. the emergence of immuno combination therapy, for liver cancer immunot
-
The world's first off-skin injection of PD-L1 antibodies! Corning Jerry KN035 (Nwolly single anti-injection) was included in the priority review by the National Drug Administration!
Time of Update: 2021-01-26
January 19, 2021 // -- Corning Jerry Biopharmaceuticals ("Corning Jerry") recently announced that its recombinant humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and develo
-
MyC, YAP1, and MMP13 gene amplification drive brain metastasis in lung cancer
Time of Update: 2021-01-26
test results from 105 BM-LUAD patient data (independent verification group) and LUAD xenotrogen transplant (PDX) mouse models received at the Medical University of Vienna from 1990 to 2013 were used to verify the role of MYC, YAP1 and MMP13 gene amplification in brain metastasis.
